Key points are not available for this paper at this time.
Abstract Background: The coronavirus disease-19 (COVID-19) has spread globally with more than 6,750,000 people infected, and nearly 400,000 patients died. Currently, we are in an urgent need for effective treatment strategy to control the clinical deterioration of COVID-19 patients.Methods: The clinical data of 10 COVID-19 patients receiving short-term moderate-dose corticosteroid (160mg/d) plus immunoglobulin (20g/d) were studied in the North Yard of The First Hospital of Changsha, Hunan from January 17th to February 27th, 2020. Epidemiological, clinical, laboratory, radiological findings were analyzed. Results: After treatment with combination of low-dose corticosteroid (40-80mg/d) and immunoglobulin (10g/d), patients’ lymphocyte count (0.88±0.34 vs 0.59±0.18, P2 (94.90±2.51 vs 90.50±5.91, P2/FiO2 (321.36±136.91 vs 129.30±64.97, P2 (90.50±5.91 vs 97.50±1.18, P2 (60.47±14.53 vs 99.07±34.31, P2/FiO2 (129.30±64.97 vs 340.86±146.72, PConclusions: Short-term moderate-dose corticosteroid plus immunoglobulin is effective for reversing the continued deterioration of COVID-19 patients who failed to respond to the low-dose therapy.
Zhou et al. (Fri,) studied this question.